Imetelstat in patients with lower-risk myelodysplastic syndromes who have relapsed or are refractory to erythropoiesis-stimulating agents (IMerge): a multinational, randomised, double-blind, placebo-controlled, phase 3 trial

作者：Uwe Platzbecker, Valeria Santini, Pierre Fenaux, Mikkael A. Sekeres, Michael R. Savona, Yazan F. Madanat, María Díez‐Campelo, David Valcárcel, Thomas Illmer, Anna Jonášová, Petra Bělohlávková, Laurie Sherman, Tymara Berry, Souria Dougherty, Sheetal Shah, Qi Xia, Libo Sun, Ying Wan, Fei Huang, Annat Ikin, Shyamala Navada, Faye Feller, Rami S. Komrokji, Amer M. Zeidan · 发表于：The Lancet · 年份：2023 · DOI：10.1016/s0140-6736(23)01724-5 · 被引用次数：137 · 研究领域：Acute Myeloid Leukemia Research、Hemoglobinopathies and Related Disorders、Telomeres, Telomerase, and Senescence